COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

被引：0
|
作者：
Vargas-Valencia, J. [1 ]
Sotelo-Guzman, M. [1 ]
Mould-Quevedo, J. F. [2 ]
Mucino-Ortega, E. [3 ]
Galindo-Suarez, R. M. [3 ]
机构：
[1] Econopharma Consulting SA CV, Mexico City, DF, Mexico
[2] Pfizer, New York, NY USA
[3] Pfizer, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.707
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A127 / A127
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN CHINA
    Zhang, Y.
    Yang, L.
    Dong, P.
    Xie, X.
    Tang, B.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A673 - A673
  • [2] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN PORTUGAL
    Mateus, C.
    Moura, A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A380 - A381
  • [3] COST-EFFECTIVENESS ANALYSIS OF LEFLUNOMIDE AS A TREATMENT FOR RHEUMATOID ARTHRITIS IN MEXICO
    Carlos-Rivera, F.
    Aguirre-Granados, A.
    Manterola, S. O. M. C.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A537 - A537
  • [4] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARKET IN ECUADOR
    Albuja, M. F.
    Torres, F. G.
    Mould, J.
    Estevez, C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [5] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN
    Guijarro, P.
    Crespo, C.
    Brosa, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [6] Cost-effectiveness analysis of etanercept vs infliximab for treatment of severe rheumatoid arthritis in Brazil
    Saggia, M. G.
    Pina, F. P.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A220 - A220
  • [7] COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS. RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO
    Gao, X.
    Hwang, S.
    Carpiuc, K. T.
    Stephens, J. M.
    Sato, R.
    Singh, A.
    Rivera, R.
    Garcia, E.
    Bierschwale, H.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A67 - A67
  • [8] Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in italy.
    Leardini, G
    Ganguly, R
    Singh, A
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S460 - S461
  • [9] Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
    Gholami, Ahmad
    Azizpoor, Jassem
    Aflaki, Elham
    Rezaee, Mehdi
    Keshavarz, Khosro
    [J]. BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [10] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
12345